Extended Methods from Pacritinib Combined with Sirolimus and Low-Dose Tacrolimus for GVHD Prevention after Allogeneic Hematopoietic Cell Transplantation: Preclinical and Phase I Trial Results

MLA

Brian C. Betts, et al. Extended Methods from Pacritinib Combined with Sirolimus and Low-Dose Tacrolimus for GVHD Prevention after Allogeneic Hematopoietic Cell Transplantation: Preclinical and Phase I Trial Results. Mar. 2023. EBSCOhost, https://doi.org/10.1158/1078-0432.22479081.v1.

APA

Brian C. Betts, Said M. Sebti, Claudio Anasetti, Bruce R. Blazar, Harshani R. Lawrence, Nicholas J. Lawrence, Shernan G. Holtan, Elizabeth M. Sagatys, Michael L. Nieder, Marco L. Davila, Rawan G. Faramand, Lia Perez, Farhad Khimani, Taiga Nishihori, Nelli Bejanyan, Asmita Mishra, Jongphil Kim, Hany Elmariah, Kelly Walton, & Joseph Pidala. (2023). Extended Methods from Pacritinib Combined with Sirolimus and Low-Dose Tacrolimus for GVHD Prevention after Allogeneic Hematopoietic Cell Transplantation: Preclinical and Phase I Trial Results. https://doi.org/10.1158/1078-0432.22479081.v1

Chicago

Brian C. Betts, Said M. Sebti, Claudio Anasetti, Bruce R. Blazar, Harshani R. Lawrence, Nicholas J. Lawrence, Shernan G. Holtan, et al. 2023. “Extended Methods from Pacritinib Combined with Sirolimus and Low-Dose Tacrolimus for GVHD Prevention after Allogeneic Hematopoietic Cell Transplantation: Preclinical and Phase I Trial Results,” March. doi:10.1158/1078-0432.22479081.v1.